News and Trends 28 Nov 2022 Molecure to conduct cancer treatment trial in Poland Molecure S.A. says the President of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products has given the company permission to conduct the first clinical trial of OATD-02. The planned phase I trial will be an open-label, multi-center, dose escalation study to evaluate safety, tolerability, anti-cancer activity and to establish the […] November 28, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2022 Replay receives $1.5M grant for hypoimmunogenic technology platform Genome writing company Replay has received a $1.56 million grant from the Bill & Melinda Gates Foundation to accelerate the development of uCell, a proprietary hypoimmunogenic technology platform. Replay’s uCell platform is an off-the-shelf, genomically rewritten, hypoimmunogenic technology that allows allogeneic donor-derived primary cells and iPSCs (induced pluripotent stem cells) to be made immune silent. […] November 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2022 Localizing BRCA gene mutations to better treat ovarian cancer Mutations of BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 people respectively, significantly increase the risk of certain cancers such as ovarian, breast, pancreatic and prostate cancer. In 2016, a new class of drugs, PARP inhibitors, was found to be highly effective against BRCA mutation-related tumors. However, almost […] November 28, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2022 Lyvgen and Bristol Myers Squibb commitment to transform cancer care Lyvgen Biopharma announced yesterday that it has started a phase 2 trial of LVGN7409 plus docetaxel or, in collaboration with Bristol Myers Squibb, nivolumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC). “Lyvgen clinical collaboration with Bristol Myers Squibb underscores our commitment to exploring combination regimens from our portfolio with complementary mechanisms of action […] November 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2022 STORM Therapeutics doses first patient with drug targeting solid tumors STORM Therapeutics Ltd, announced today that the first patient in a phase 1 study had been dosed with a drug targeting solid tumors. The biotech company works on discovering and developing new small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. The patient was dosed with STC-15, STORM’s clinical candidate. It […] November 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Nov 2022 XtalPi and CK Life Sciences partner on tumor vaccine R&D XtalPi has entered into a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. The goal is to jointly develop a novel artificial intelligence (AI) tumor vaccine R&D platform. This will improve the discovery and design capabilities of tumor vaccines and accelerate development of more vaccine types. According to public information, […] November 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Nov 2022 AI works on artificial DNA for future drug development With the help of artificial intelligence (AI), researchers at Chalmers University of Technology in Sweden have succeeded in designing synthetic DNA that controls the cells’ protein production. The technology can contribute to the development and production of vaccines, drugs for severe diseases, as well as alternative food proteins much faster and at significantly lower costs […] November 24, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Nov 2022 BC Platforms partners on AI-driven EU cancer data project BC Platforms (BCP), a provider of healthcare data management and analytics, has been chosen as a key partner in a European Commission (EC) project. Under the EC’s Horizon Europe program, Helsinki University Hospital (HUS), has been awarded a contract to lead a €7 million ($7.2 million) consortium project termed ONCOVALUE. BCP will work with HUS […] November 24, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 Significant therapeutic potential of OSE Immunotherapeutics’ CLEC-1 published OSE Immunotherapeutics SA has announced the publication of data in the peer-reviewed journal Science Advances on a first-in-class preclinical program with CLEC-1, its novel myeloid immune checkpoint target for cancer immunotherapy. The academic collaboration conducted with Elise Chiffoleau’s team at the Center for Translational Research in Transplantation and Immunology has led to identify CLEC-1 as […] November 23, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2022 Achilles Therapeutics receives US patent for immunotherapies A U.S. patent has been granted to Achilles Therapeutics plc for the treatment of patients with an immunotherapy, including vaccine, antibody and autologous T cell therapy approaches, targeting clonal neoantigens identified using the Achilles Clonality Engine (ACE). ACE is a proprietary method for determining clonality of patient-specific mutations that drives the PELEUS bioinformatics platform. Clonal […] November 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2022 CatalYm raises €50M to boost solid tumors trial CatalYm has announced the close of a €50 million ($49 million) series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. The financing will support the clinical development of its […] November 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2022 FogPharma raises $178M to target cancer U.S biotech company FogPharma has announced a $178 million series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, funds and accounts advised by T. Rowe Price Associates, Inc., Invus, Farallon Capital Management, […] November 21, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email